Mary is a cross sectoral specialist with two decades of board and C-suite Executive experience and a breadth of expertise across all aspects of business management in the biotechnology, pharmaceutical, health and agricultural spheres. 

She is currently Executive Director (acting) of the Global Health Alliance; Chair of unlisted oncology company, CTxONE and Executive Director of Mary Harney Advisory.

Recently, Mary was the Interim CEO of the $2b Breakthrough Victoria fund. In her prior roles as CEO of Royal Australasian College of Surgeons, and Gardiner Dairy Research Foundation; the Director of the Office of Clinical Research/COO Research at Peter MacCallum Cancer Centre and Director of Corporate Development at Bioproperties Pty Ltd, she had carriage of strategy development, risk management and the development of best practice corporate, research and clinical governance.

Mary held the Company Secretary role on three occasions since 2000 at Cerylid Biosciences Ltd, the Gardiner Dairy Research Foundation and the Royal Australasian College of Surgeons. She was on the board of the RACS Foundation for Surgery and board committees (Audit and Risk Committees, Governance and People Development) for RACS and Gardiner Foundation. 

Mary has undergraduate degrees in science and art history from Monash University and University of Melbourne respectively and international postgraduate qualifications in diagnostic Cytopathology. In 2015, she was the collaborative winner, with Monash of the AFR and B-HERT for excellence in collaboration between industry and academia for the dairy industry. In 2016, she was awarded the Science Alumni of the Year award from Monash University.

Mary is a Fellow of the Institute of Managers, Member of the Australian Institute of Company Directors (AICD) and completed the AICD course in 2000. In 2017, she completed ‘Strategy in the Age of Digital Disruption’ at INSEAD Business School (Global #1 Business School)

To view Mary Harney’s LinkedIn profile